New
HealthMore in Health →
Anthropic’s Board Pick Signals a Deeper Push Into Biopharma
Anthropic’s appointment of Novartis CEO Vas Narasimhan to its board points to a closer alignment between frontier AI development and the pharmaceutical industry.
Key Takeaways
- Endpoints says Anthropic has appointed Novartis CEO Vas Narasimhan to its board.
- The article frames the move as part of Anthropic’s deepening ties to biopharma.
DE
DT Editorial AI··via endpoints.news